Beverly James

Professor Allen

Spanish 4003

12/6/2016

 

INSUFICIENCIA CARDIACA

Insuf Card 2016; 11 (3): 115-121

 

                                     Pulmonary arterial hypertension in adult congenital heart disease 

                                                                        Impact and outcome 

                                                          Data from the GUTI-GUCH Registry

 

Claudio Gabriel Moros, Marisa Pacheco Otero, Gianina Faliva, Maria del Carmen Rubio,

Mariana Lopez Daneri, Isabel Torres, Ines Abella, Alvaro Sosa Liprandi,

Liliana Noemi Nicolosi, Maria Grippo

 

 Introduction 

 The adult congenital heart disease (ACHD) is one of the fastest growing subgroups within cardiology in the last years due to precocious diagnosis and the progress of surgical and endovascular treatments. It is calculated that 85-90% of patients with congenital heart disease will reach adulthood. The sequelae and complications generated by the survival of these patients result in higher rates of hospitalizations, new surgeries and other proceedings.

Currently being the most frequent cause of pulmonary arterial hypertension (PAH) after the connective tissue disease, it is estimated that throughout the progression of ACHD, 5-10% of its patients will develop pulmonary hypertension (PH). Its occurrence is related to a worst prognosis.

The objective of the present study was to analyze the epidemiological characteristics, clinical and pharmacological treatments in patients with PAH and their impact on survival.